Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
less,1815435,clearance,Two slow metabolizers were identified (clearance less than 0.10 L/kg/h).,Early individualization of tricyclic antidepressant dosing using a Bayesian pharmacokinetic model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815435/),[l] / [h·kg],0.10,8081,DB01142,Doxepin
,12162857,fraction absorbed,The mean fraction absorbed after oral administration was 0.29 for each isomer.,Absolute bioavailability and stereoselective pharmacokinetics of doxepin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12162857/),,0.29,10422,DB01142,Doxepin
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,7.8,30263,DB01142,Doxepin
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,11.6,30264,DB01142,Doxepin
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,16,30265,DB01142,Doxepin
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,17.8,30266,DB01142,Doxepin
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,20.9,30267,DB01142,Doxepin
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,31,30268,DB01142,Doxepin
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,35,30269,DB01142,Doxepin
,3582480,steady state plasma levels,"Unlike ranitidine, cimetidine co-administration resulted in a significant increase in steady state plasma levels of doxepin (4.7, 9.0 and 4.5 ng/ml during Treatments A, B and C respectively) but not desmethyldoxepin (4.1, 4.6 and 4.2 ng/ml during Treatments A, B and C respectively).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),[ng] / [ml],4.7,31995,DB01142,Doxepin
,3582480,steady state plasma levels,"Unlike ranitidine, cimetidine co-administration resulted in a significant increase in steady state plasma levels of doxepin (4.7, 9.0 and 4.5 ng/ml during Treatments A, B and C respectively) but not desmethyldoxepin (4.1, 4.6 and 4.2 ng/ml during Treatments A, B and C respectively).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),[ng] / [ml],9.0,31996,DB01142,Doxepin
,3582480,steady state plasma levels,"Unlike ranitidine, cimetidine co-administration resulted in a significant increase in steady state plasma levels of doxepin (4.7, 9.0 and 4.5 ng/ml during Treatments A, B and C respectively) but not desmethyldoxepin (4.1, 4.6 and 4.2 ng/ml during Treatments A, B and C respectively).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),[ng] / [ml],4.5,31997,DB01142,Doxepin
,3582480,steady state plasma levels,"Unlike ranitidine, cimetidine co-administration resulted in a significant increase in steady state plasma levels of doxepin (4.7, 9.0 and 4.5 ng/ml during Treatments A, B and C respectively) but not desmethyldoxepin (4.1, 4.6 and 4.2 ng/ml during Treatments A, B and C respectively).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),[ng] / [ml],4.1,31998,DB01142,Doxepin
,3582480,steady state plasma levels,"Unlike ranitidine, cimetidine co-administration resulted in a significant increase in steady state plasma levels of doxepin (4.7, 9.0 and 4.5 ng/ml during Treatments A, B and C respectively) but not desmethyldoxepin (4.1, 4.6 and 4.2 ng/ml during Treatments A, B and C respectively).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),[ng] / [ml],4.6,31999,DB01142,Doxepin
,3582480,steady state plasma levels,"Unlike ranitidine, cimetidine co-administration resulted in a significant increase in steady state plasma levels of doxepin (4.7, 9.0 and 4.5 ng/ml during Treatments A, B and C respectively) but not desmethyldoxepin (4.1, 4.6 and 4.2 ng/ml during Treatments A, B and C respectively).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),[ng] / [ml],4.2,32000,DB01142,Doxepin
,3582480,Elimination half-lives,"Elimination half-lives of doxepin and desmethyldoxepin were prolonged by cimetidine co-administration (19.6 and 26.2 h respectively), but remained unchanged during the ranitidine treatment phase (13.3 and 18.4 h) as compared to the control phase i.e. Treatment A (13.2 and 19.0 h).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),h,19.6,32001,DB01142,Doxepin
,3582480,Elimination half-lives,"Elimination half-lives of doxepin and desmethyldoxepin were prolonged by cimetidine co-administration (19.6 and 26.2 h respectively), but remained unchanged during the ranitidine treatment phase (13.3 and 18.4 h) as compared to the control phase i.e. Treatment A (13.2 and 19.0 h).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),h,26.2,32002,DB01142,Doxepin
,3582480,Elimination half-lives,"Elimination half-lives of doxepin and desmethyldoxepin were prolonged by cimetidine co-administration (19.6 and 26.2 h respectively), but remained unchanged during the ranitidine treatment phase (13.3 and 18.4 h) as compared to the control phase i.e. Treatment A (13.2 and 19.0 h).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),h,13.3,32003,DB01142,Doxepin
,3582480,Elimination half-lives,"Elimination half-lives of doxepin and desmethyldoxepin were prolonged by cimetidine co-administration (19.6 and 26.2 h respectively), but remained unchanged during the ranitidine treatment phase (13.3 and 18.4 h) as compared to the control phase i.e. Treatment A (13.2 and 19.0 h).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),h,18.4,32004,DB01142,Doxepin
,3582480,Elimination half-lives,"Elimination half-lives of doxepin and desmethyldoxepin were prolonged by cimetidine co-administration (19.6 and 26.2 h respectively), but remained unchanged during the ranitidine treatment phase (13.3 and 18.4 h) as compared to the control phase i.e. Treatment A (13.2 and 19.0 h).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),h,13.2,32005,DB01142,Doxepin
,3582480,Elimination half-lives,"Elimination half-lives of doxepin and desmethyldoxepin were prolonged by cimetidine co-administration (19.6 and 26.2 h respectively), but remained unchanged during the ranitidine treatment phase (13.3 and 18.4 h) as compared to the control phase i.e. Treatment A (13.2 and 19.0 h).",The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582480/),h,19.0,32006,DB01142,Doxepin
,7293791,Peak serum concentrations,Peak serum concentrations of DOX were observed at 1-2 hours and they ranged between 59.1-107.4 nmol/1.,Single dose pharmacokinetics of doxepin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7293791/),nM,59.1-107.4,48441,DB01142,Doxepin
,7293791,distribution half-life,DOX disappearance was biphasic with a mean distribution half-life of 2.0 hrs and elimination half-life of 17.9 hrs.,Single dose pharmacokinetics of doxepin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7293791/),h,2.0,48442,DB01142,Doxepin
,7293791,elimination half-life,DOX disappearance was biphasic with a mean distribution half-life of 2.0 hrs and elimination half-life of 17.9 hrs.,Single dose pharmacokinetics of doxepin in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7293791/),h,17.9,48443,DB01142,Doxepin
,7293791,total apparent volume of distribution,The mean total apparent volume of distribution was 22.7 l/kg and plasma clearance 0.93 l/hr/kg.,Single dose pharmacokinetics of doxepin in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7293791/),[l] / [kg],22.7,48444,DB01142,Doxepin
,7293791,plasma clearance,The mean total apparent volume of distribution was 22.7 l/kg and plasma clearance 0.93 l/hr/kg.,Single dose pharmacokinetics of doxepin in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7293791/),[l] / [h·kg],0.93,48445,DB01142,Doxepin
,7293791,apparent half-life,DDOX elimination was monophasic with a mean apparent half-life of 28.5 hours.,Single dose pharmacokinetics of doxepin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7293791/),h,28.5,48446,DB01142,Doxepin
,7293791,protein binding,Equilibrium dialysis gave a mean protein binding of 75.5% for DOX and 76.0% for DDOX.,Single dose pharmacokinetics of doxepin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7293791/),%,75.5,48447,DB01142,Doxepin
,7293791,protein binding,Equilibrium dialysis gave a mean protein binding of 75.5% for DOX and 76.0% for DDOX.,Single dose pharmacokinetics of doxepin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7293791/),%,76.0,48448,DB01142,Doxepin
,31338198,H1ROs,"Brain H1ROs after desloratadine and loratadine administration were 6.47 ± 10.5% and 13.8 ± 7.00%, respectively (P = 0.103).",Brain histamine H1 receptor occupancy after oral administration of desloratadine and loratadine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31338198/),%,6.47,53647,DB01142,Doxepin
,31338198,H1ROs,"Brain H1ROs after desloratadine and loratadine administration were 6.47 ± 10.5% and 13.8 ± 7.00%, respectively (P = 0.103).",Brain histamine H1 receptor occupancy after oral administration of desloratadine and loratadine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31338198/),%,13.8,53648,DB01142,Doxepin
,3133701,dose-normalized steady-state concentration,"The mean (SEM) values of the dose-normalized steady-state concentration and the apparent clearance after oral administration of this drug were 25.8 (4.8) ng.ml-1/mg.kg-1 and 2.529 (0.342) 1.h-1.kg-1, respectively.",Steady-state kinetics of doxepin and imipramine in Saudi patients with interethnic comparison. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3133701/),[ng] / [kg·mg·ml],25.8,53811,DB01142,Doxepin
,3133701,apparent clearance,"The mean (SEM) values of the dose-normalized steady-state concentration and the apparent clearance after oral administration of this drug were 25.8 (4.8) ng.ml-1/mg.kg-1 and 2.529 (0.342) 1.h-1.kg-1, respectively.",Steady-state kinetics of doxepin and imipramine in Saudi patients with interethnic comparison. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3133701/),[1] / [h·kg],2.529,53812,DB01142,Doxepin
,3133701,dose-normalized steady-state concentration,"The mean dose-normalized steady-state concentration of IMI was 68.3 (19.7) ng.ml-1/mg.kg-1, and the mean apparent clearance after oral administration of IMI was 1.619 (0.353) 1.h-1. kg-1.",Steady-state kinetics of doxepin and imipramine in Saudi patients with interethnic comparison. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3133701/),[ng] / [kg·mg·ml],68.3,53813,DB01142,Doxepin
,3133701,apparent clearance,"The mean dose-normalized steady-state concentration of IMI was 68.3 (19.7) ng.ml-1/mg.kg-1, and the mean apparent clearance after oral administration of IMI was 1.619 (0.353) 1.h-1. kg-1.",Steady-state kinetics of doxepin and imipramine in Saudi patients with interethnic comparison. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3133701/),[1] / [h·kg],1.619,53814,DB01142,Doxepin
,6636256,Absolute recoveries,Absolute recoveries were 87-97%.,Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),%,87-97,96511,DB01142,Doxepin
,6636256,Detection limits,"Detection limits under the conditions described were 2 ng/ml for AMI, DOX, and IMI, 4 ng/ml for NORT, DESDOX, and DESIP, and 10 ng/ml for PRO.",Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),[ng] / [ml],2,96512,DB01142,Doxepin
,6636256,Detection limits,"Detection limits under the conditions described were 2 ng/ml for AMI, DOX, and IMI, 4 ng/ml for NORT, DESDOX, and DESIP, and 10 ng/ml for PRO.",Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),[ng] / [ml],4,96513,DB01142,Doxepin
,6636256,Detection limits,"Detection limits under the conditions described were 2 ng/ml for AMI, DOX, and IMI, 4 ng/ml for NORT, DESDOX, and DESIP, and 10 ng/ml for PRO.",Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),[ng] / [ml],10,96514,DB01142,Doxepin
less,6636256,total assay time,The total assay time was less than 10 min for DESIP and 12 min for PRO.,Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),min,10,96515,DB01142,Doxepin
,6636256,total assay time,The total assay time was less than 10 min for DESIP and 12 min for PRO.,Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),min,12,96516,DB01142,Doxepin
,17665858,recovery,The recovery ranged from 86.1 to 94.5% for mianserin.,"Development, validation and application of the HPLC method for determination of mianserin in human serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17665858/),%,86.1,131385,DB01142,Doxepin
,17665858,recovery,The recovery ranged from 86.1 to 94.5% for mianserin.,"Development, validation and application of the HPLC method for determination of mianserin in human serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17665858/),%,94,131386,DB01142,Doxepin
,11304934,AUC0-infinity,"Values of 193,463 pgh/ml (test preparation) and 197,988 pg h/ml (reference preparation) for doxepin as well as values of 313,298 pg h/ml (test preparation) and 306,663 pgh/ml (reference preparation) for N-desmethyldoxepin for the parameter AUC0-infinity demonstrate a nearly identical extent of drug absorption.",Bioavailability investigation of two different oral formulations of doxepin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304934/),[h·pg] / [ml],"313,298",138720,DB01142,Doxepin
,11304934,AUC0-infinity,"Values of 193,463 pgh/ml (test preparation) and 197,988 pg h/ml (reference preparation) for doxepin as well as values of 313,298 pg h/ml (test preparation) and 306,663 pgh/ml (reference preparation) for N-desmethyldoxepin for the parameter AUC0-infinity demonstrate a nearly identical extent of drug absorption.",Bioavailability investigation of two different oral formulations of doxepin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304934/),[pgh] / [ml],"306,663",138721,DB01142,Doxepin
,11304934,Maximum concentrations (Cmax),"Maximum concentrations (Cmax) for doxepin/N-desmethyldoxepin of 15,960.06/6,883.69 pg/ml and 18,614.73/6,846.62 pg/ml were achieved for test and reference preparation.",Bioavailability investigation of two different oral formulations of doxepin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304934/),[pg] / [ml],"15,960.06",138722,DB01142,Doxepin
,11304934,Maximum concentrations (Cmax),"Maximum concentrations (Cmax) for doxepin/N-desmethyldoxepin of 15,960.06/6,883.69 pg/ml and 18,614.73/6,846.62 pg/ml were achieved for test and reference preparation.",Bioavailability investigation of two different oral formulations of doxepin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304934/),[pg] / [ml],"6,883.69",138723,DB01142,Doxepin
,11304934,Maximum concentrations (Cmax),"Maximum concentrations (Cmax) for doxepin/N-desmethyldoxepin of 15,960.06/6,883.69 pg/ml and 18,614.73/6,846.62 pg/ml were achieved for test and reference preparation.",Bioavailability investigation of two different oral formulations of doxepin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304934/),[pg] / [ml],"18,614.73",138724,DB01142,Doxepin
,11304934,Maximum concentrations (Cmax),"Maximum concentrations (Cmax) for doxepin/N-desmethyldoxepin of 15,960.06/6,883.69 pg/ml and 18,614.73/6,846.62 pg/ml were achieved for test and reference preparation.",Bioavailability investigation of two different oral formulations of doxepin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304934/),[pg] / [ml],"6,846.62",138725,DB01142,Doxepin
,11304934,Time to reach doxepin maximum plasma concentration (tmax),Time to reach doxepin maximum plasma concentration (tmax) was 1.98 h for both preparations and for N-desmethyldoxepin tmax was 4.52 h (test preparation) and 4.15 h (reference preparation).,Bioavailability investigation of two different oral formulations of doxepin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304934/),h,1.98,138726,DB01142,Doxepin
,11304934,tmax,Time to reach doxepin maximum plasma concentration (tmax) was 1.98 h for both preparations and for N-desmethyldoxepin tmax was 4.52 h (test preparation) and 4.15 h (reference preparation).,Bioavailability investigation of two different oral formulations of doxepin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304934/),h,4.52,138727,DB01142,Doxepin
,11304934,tmax,Time to reach doxepin maximum plasma concentration (tmax) was 1.98 h for both preparations and for N-desmethyldoxepin tmax was 4.52 h (test preparation) and 4.15 h (reference preparation).,Bioavailability investigation of two different oral formulations of doxepin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304934/),h,4.15,138728,DB01142,Doxepin
,3950073,time to peak doxepin plasma concentration,"Doxepin absorptive parameters--time to peak doxepin plasma concentration (2.3, control, vs. 2.4 hours during cimetidine co-administration) and peak concentration achieved (43.3. vs. 55.5 ng/ml)--were not changed during cimetidine administration.",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),h,2.3,145342,DB01142,Doxepin
,3950073,time to peak doxepin plasma concentration,"Doxepin absorptive parameters--time to peak doxepin plasma concentration (2.3, control, vs. 2.4 hours during cimetidine co-administration) and peak concentration achieved (43.3. vs. 55.5 ng/ml)--were not changed during cimetidine administration.",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),h,2.4,145343,DB01142,Doxepin
,3950073,peak concentration achieved,"Doxepin absorptive parameters--time to peak doxepin plasma concentration (2.3, control, vs. 2.4 hours during cimetidine co-administration) and peak concentration achieved (43.3. vs. 55.5 ng/ml)--were not changed during cimetidine administration.",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),[ng] / [ml],43.3,145344,DB01142,Doxepin
,3950073,peak concentration achieved,"Doxepin absorptive parameters--time to peak doxepin plasma concentration (2.3, control, vs. 2.4 hours during cimetidine co-administration) and peak concentration achieved (43.3. vs. 55.5 ng/ml)--were not changed during cimetidine administration.",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),[ng] / [ml],55.5,145345,DB01142,Doxepin
,3950073,elimination half-life,"Likewise, doxepin elimination half-life was similar in the control state (12.5 hours) and during cimetidine administration (13.2 hours).",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),h,12.5,145346,DB01142,Doxepin
,3950073,elimination half-life,"Likewise, doxepin elimination half-life was similar in the control state (12.5 hours) and during cimetidine administration (13.2 hours).",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),h,13.2,145347,DB01142,Doxepin
,3950073,area under the plasma concentration-time curve (AUC),"However, doxepin area under the plasma concentration-time curve (AUC) was increased during concurrent cimetidine administration (533 vs. 695 ng/ml . hour; p less than 0.05), resulting in a trend toward decreased doxepin oral clearance (4404 vs. 3278 ml/min; 0.05 less than p less than 0.1).",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),[ng] / [h·ml],533,145348,DB01142,Doxepin
,3950073,area under the plasma concentration-time curve (AUC),"However, doxepin area under the plasma concentration-time curve (AUC) was increased during concurrent cimetidine administration (533 vs. 695 ng/ml . hour; p less than 0.05), resulting in a trend toward decreased doxepin oral clearance (4404 vs. 3278 ml/min; 0.05 less than p less than 0.1).",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),[ng] / [h·ml],695,145349,DB01142,Doxepin
,3950073,oral clearance,"However, doxepin area under the plasma concentration-time curve (AUC) was increased during concurrent cimetidine administration (533 vs. 695 ng/ml . hour; p less than 0.05), resulting in a trend toward decreased doxepin oral clearance (4404 vs. 3278 ml/min; 0.05 less than p less than 0.1).",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),[ml] / [min],4404,145350,DB01142,Doxepin
,3950073,oral clearance,"However, doxepin area under the plasma concentration-time curve (AUC) was increased during concurrent cimetidine administration (533 vs. 695 ng/ml . hour; p less than 0.05), resulting in a trend toward decreased doxepin oral clearance (4404 vs. 3278 ml/min; 0.05 less than p less than 0.1).",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),[ml] / [min],3278,145351,DB01142,Doxepin
,3950073,Relative bioavailability,Relative bioavailability during concurrent cimetidine treatment was 123% of that during the control trial.,Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),%,123,145352,DB01142,Doxepin
,3950073,AUC,"Desmethyldoxepin AUC was no different between trials (478, control, vs. 433 ng/ml . hour during cimetidine ingestion).",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),[ng] / [h·ml],478,145353,DB01142,Doxepin
,3950073,AUC,"Desmethyldoxepin AUC was no different between trials (478, control, vs. 433 ng/ml . hour during cimetidine ingestion).",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),[ng] / [h·ml],433,145354,DB01142,Doxepin
,3950073,percent unbound,"Plasma protein binding of doxepin was similar between trials (percent unbound; 10.5, control, vs. 11.2%) and therefore did not influence calculated AUC.",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),%,10.5,145355,DB01142,Doxepin
,3950073,percent unbound,"Plasma protein binding of doxepin was similar between trials (percent unbound; 10.5, control, vs. 11.2%) and therefore did not influence calculated AUC.",Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950073/),%,11.2,145356,DB01142,Doxepin
,12360109,clearance,"Mean E-doxepin clearance (95% confidence interval) was 406 (390-445), 247 (241-271), and 127 (124-139) l h(-1) in EMs, IMs and PMs of CYP2D6.","Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12360109/),[l] / [h],406,146918,DB01142,Doxepin
,12360109,clearance,"Mean E-doxepin clearance (95% confidence interval) was 406 (390-445), 247 (241-271), and 127 (124-139) l h(-1) in EMs, IMs and PMs of CYP2D6.","Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12360109/),[l] / [h],247,146919,DB01142,Doxepin
,12360109,clearance,"Mean E-doxepin clearance (95% confidence interval) was 406 (390-445), 247 (241-271), and 127 (124-139) l h(-1) in EMs, IMs and PMs of CYP2D6.","Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12360109/),[l] / [h],127,146920,DB01142,Doxepin
,12360109,oral clearance,E-doxepin oral clearance was also significantly lower in carriers of CYP2C9*3/*3 (238 l h(-1) ).,"Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12360109/),[l] / [h],238,146921,DB01142,Doxepin
,12360109,oral clearances,CYP2C19 was involved in Z-doxepin metabolism with 2.5-fold differences in oral clearances (73 l h(-1) in CYP2C19 PMs compared with 191 l h(-1) in EMs).,"Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12360109/),[l] / [h],73,146922,DB01142,Doxepin
,12360109,oral clearances,CYP2C19 was involved in Z-doxepin metabolism with 2.5-fold differences in oral clearances (73 l h(-1) in CYP2C19 PMs compared with 191 l h(-1) in EMs).,"Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12360109/),[l] / [h],191,146923,DB01142,Doxepin
,12360109,area under the curve (0-48 h),"The area under the curve (0-48 h) of the active metabolite -desmethyldoxepin was dependent on CYP2D6 genotype with a median of 5.28, 1.35, and 1.28 nmol l h(-1) in PMs, IMs, and EMs of CYP2D6.","Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12360109/),[l·nM] / [h],5.28,146924,DB01142,Doxepin
,12360109,area under the curve (0-48 h),"The area under the curve (0-48 h) of the active metabolite -desmethyldoxepin was dependent on CYP2D6 genotype with a median of 5.28, 1.35, and 1.28 nmol l h(-1) in PMs, IMs, and EMs of CYP2D6.","Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12360109/),[l·nM] / [h],1.35,146925,DB01142,Doxepin
,12360109,area under the curve (0-48 h),"The area under the curve (0-48 h) of the active metabolite -desmethyldoxepin was dependent on CYP2D6 genotype with a median of 5.28, 1.35, and 1.28 nmol l h(-1) in PMs, IMs, and EMs of CYP2D6.","Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12360109/),[l·nM] / [h],1.28,146926,DB01142,Doxepin
,20954218,recovery,"The recovery was 85.3, 88.4 and 80.7% for amitriptyline, nortriptyline and doxepin respectively.",Development and validation of amitriptyline and its metabolite in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954218/),%,85.3,154839,DB01142,Doxepin
,20954218,recovery,"The recovery was 85.3, 88.4 and 80.7% for amitriptyline, nortriptyline and doxepin respectively.",Development and validation of amitriptyline and its metabolite in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954218/),%,88.4,154840,DB01142,Doxepin
,20954218,recovery,"The recovery was 85.3, 88.4 and 80.7% for amitriptyline, nortriptyline and doxepin respectively.",Development and validation of amitriptyline and its metabolite in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954218/),%,80.7,154841,DB01142,Doxepin
,20954218,Total run time,"Total run time was 1.2 min only for each sample, which makes it possible to analyze more than 400 samples per day.",Development and validation of amitriptyline and its metabolite in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954218/),min,1.2,154842,DB01142,Doxepin
,32879225,activation energy (Ea),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ΔS) was -80.73 J/K·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[kj] / [mol],88.70,195214,DB01142,Doxepin
,32879225,activation entropy (ΔS),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ΔS) was -80.73 J/K·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[j] / [k·mol],-,195215,DB01142,Doxepin
,32879225,activation entropy (ΔS),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ΔS) was -80.73 J/K·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[j] / [k·mol],80.73,195216,DB01142,Doxepin
,32879225,retention times,"In the AMX degradation experiment, peaks considered to be degradation products A (I) and B (II) were detected at retention times of around 3 min and 30 min in LC/UV measurements, respectively.",Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),min,3,195217,DB01142,Doxepin
,32879225,retention times,"In the AMX degradation experiment, peaks considered to be degradation products A (I) and B (II) were detected at retention times of around 3 min and 30 min in LC/UV measurements, respectively.",Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),min,30,195218,DB01142,Doxepin
,16390347,H(1)R,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,16.7,246573,DB01142,Doxepin
,16390347,H(1)R,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,77.7,246574,DB01142,Doxepin
,16390347,H(1)R,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,14.7,246575,DB01142,Doxepin
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,16.7,246576,DB01142,Doxepin
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,77.7,246577,DB01142,Doxepin
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,14.1,246578,DB01142,Doxepin
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,85.9,246579,DB01142,Doxepin
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,14.7,246580,DB01142,Doxepin
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,76.1,246581,DB01142,Doxepin
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,12.8,246582,DB01142,Doxepin
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,69.7,246583,DB01142,Doxepin
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,12.5,246584,DB01142,Doxepin
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,66.5,246585,DB01142,Doxepin
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,13.9,246586,DB01142,Doxepin
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,65.8,246587,DB01142,Doxepin
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,19.5,246588,DB01142,Doxepin
,16390347,occupancies,"Mean H(1)R occupancies for olopatadine and ketotifen were, respectively: MPFC, 16.7 vs. 77.7; DLPFC, 14.1 vs. 85.9; ACC, 14.7 vs. 76.1; IC, 12.8 vs. 69.7; TC, 12.5 vs. 66.5; PC, 13.9 vs. 65.8; and OC, 19.5 vs. 60.6.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),,60.6,246589,DB01142,Doxepin
,16390347,occupancy,"Overall cortical mean H(1)R occupancy of olopatadine and ketotifen were 15% and 72%, respectively.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),%,15,246590,DB01142,Doxepin
,16390347,occupancy,"Overall cortical mean H(1)R occupancy of olopatadine and ketotifen were 15% and 72%, respectively.",Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390347/),%,72,246591,DB01142,Doxepin
,16007002,AUC,"A trend for lower AUC of the active principle (sum of doxepin and N-desmethyldoxepin) in UMs versus EMs was detected (575 versus 1,000 nmol h/l, P=0.07), mainly due to the differences in desmethyldoxepin concentrations (P=0.003).",Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16007002/),[h·nM] / [l],575,267781,DB01142,Doxepin
,16007002,AUC,"A trend for lower AUC of the active principle (sum of doxepin and N-desmethyldoxepin) in UMs versus EMs was detected (575 versus 1,000 nmol h/l, P=0.07), mainly due to the differences in desmethyldoxepin concentrations (P=0.003).",Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16007002/),[h·nM] / [l],"1,000",267782,DB01142,Doxepin
